Amicus Therapeutics (NASDAQ:FOLD) is scheduled to announce its earnings results before the market opens on Tuesday, February 27th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter.
Amicus Therapeutics (NASDAQ:FOLD) opened at $15.24 on Friday. The company has a market capitalization of $2,560.00, a P/E ratio of -8.33 and a beta of 1.45. The company has a debt-to-equity ratio of 0.39, a current ratio of 6.32 and a quick ratio of 6.22. Amicus Therapeutics has a one year low of $5.87 and a one year high of $17.40.
FOLD has been the subject of a number of recent research reports. BidaskClub upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, December 27th. Cowen reiterated a “buy” rating and set a $22.00 price objective on shares of Amicus Therapeutics in a research note on Wednesday, January 10th. Robert W. Baird set a $20.00 price objective on Amicus Therapeutics and gave the company a “buy” rating in a research note on Wednesday, February 7th. ValuEngine upgraded Amicus Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, Zacks Investment Research upgraded Amicus Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, January 17th. One research analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $19.06.
In other Amicus Therapeutics news, insider Jay Barth sold 20,000 shares of Amicus Therapeutics stock in a transaction on Tuesday, January 23rd. The stock was sold at an average price of $16.80, for a total value of $336,000.00. Following the completion of the sale, the insider now owns 105,409 shares of the company’s stock, valued at approximately $1,770,871.20. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO John F. Crowley sold 47,213 shares of Amicus Therapeutics stock in a transaction on Monday, December 4th. The stock was sold at an average price of $13.61, for a total value of $642,568.93. Following the completion of the sale, the chief executive officer now directly owns 375,214 shares of the company’s stock, valued at approximately $5,106,662.54. The disclosure for this sale can be found here. Insiders have sold 250,390 shares of company stock valued at $3,620,581 in the last quarter. 3.40% of the stock is owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “Amicus Therapeutics (FOLD) Set to Announce Quarterly Earnings on Tuesday” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/02/25/amicus-therapeutics-fold-set-to-announce-quarterly-earnings-on-tuesday.html.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.